Top 5 Target	Count

H1 receptor(Histamine H1 receptor)	2
P2Y12 receptor(Purinergic receptor P2Y12)	1
LPAR1(Lysophosphatidic acid receptor Edg-2)	1
PDL1(Programmed death-ligand 1)	1
chymase	1

Drugs associated with UBE Corp.

Omidenepag Isopropyl

Target

EP2

Mechanism

EP2 agonists

Active Org.

Santen Pharmaceutical Co., Ltd. [+2]

Originator Org.

UBE Corp.

Active Indication

Glaucoma [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date21 Sep 2018

Prasugrel Hydrochloride

Target

P2Y12 receptor

Mechanism

P2Y12 receptor antagonists

Active Org.

Mylan NV [+4]

Originator Org.

Daiichi Sankyo Co., Ltd.

Active Indication

Brain Ischemia [+7]

Inactive Indication

Acrocallosal Syndrome [+3]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

EU [+3]

First Approval Date24 Feb 2009

Bepotastine salicylate

Target

H1 receptor

Mechanism

H1 receptor antagonists

Active Org.

UBE Corp. [+3]

Originator Org.

Hanlim Pharm Co., Ltd.

Active Indication

Hypersensitivity [+3]

Inactive Indication

Respiration Disorders [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date27 Oct 2000

Clinical Trials associated with UBE Corp.

JPRN-UMIN000053727 / Completed

Association of peripheral nerve block under general anesthesia on postoperative nausea and vomiting: a nationwide population-based study - Association of peripheral nerve block under general anesthesia on postoperative nausea and vomiting: a nationwide population-based study

Start Date28 Feb 2024

Sponsor / Collaborator

Ube Industries Central Hospital Corp.

JPRN-UMIN000039346 / Recruiting

The incidence of phrenic nerve palsy after Clavipectoral fascial plane block - The incidence of phrenic nerve palsy after Clavipectoral fascial plane block

Start Date01 Jan 2020

Sponsor / Collaborator

Ube Industries Central Hospital Corp.

JPRN-UMIN000037866 / Completed

Examination of fascia illiac block area using thermography - Examination of fascia illiac block area using thermography

Start Date31 Aug 2019

Sponsor / Collaborator

Ube Industries Central Hospital Corp.

100 Clinical Results associated with UBE Corp.

0 Patents (Medical) associated with UBE Corp.

2,012

Literatures (Medical) associated with UBE Corp.

01 Sep 2024·Journal of Clinical Anesthesia

Development and validation of a machine learning model to predict postoperative delirium using a nationwide database: A retrospective, observational study

Article

Author: Koga, Mami ; Shiramoto, Hiroko ; Morimoto, Yasuhiro ; Yoshimura, Manabu

STUDY OBJECTIVEPostoperative delirium is a neuropsychological syndrome that typically occurs in surgical patients. Its onset can lead to prolonged hospitalization as well as increased morbidity and mortality. Therefore, it is important to promptly identify its signs. This study aimed to develop and validate a machine learning predictive model for postoperative delirium using extensive population data.DESIGNRetrospective observational study.SETTINGJapanese Diagnosis Procedure Combination inpatient data. Data were used for internal (2016.4-2018.12) and temporal validation (2019.01-2019.10).PATIENTSPatients aged ≥65 years who underwent general anesthesia for surgical procedure.MEASUREMENTSThe primary outcome was postoperative delirium, which was defined as a condition requiring newly prescribed antipsychotic drugs or assignment of the corresponding insurance claim code after the date of surgery. We trained and tuned the optimal machine-learning model through 10-fold cross-validation using the selected optimal area under the receiver operating characteristic curve (AUC) value. In the temporal validation, we measured the performance of our model.MAIN RESULTSThe analysis included 557,990 patients. The light-gradient boosting machine models showed a higher AUC value (0.826 [95% confidence interval (CI): 0.822-0.829]) than the other models. Regarding performance, the model had a recall value of 0.124 (95% CI: 0.119-0.129) and precision value of 0.659 (95% CI: 0.641-0.677]). This performance was sustained in the temporal validation (AUC, 0.815 [95% CI: 0.811-0.818]). At a sensitivity of 0.80, the model achieved a specificity of 0.672 (95% CI: 0.670-0.674]), a negative predictive value of 0.975 (95% CI: 0.974-0.975), and a positive predictive value of 0.176 (95% CI: 0.176-0.179).CONCLUSIONSUsing extensive Diagnostic Procedure Combination data, we successfully created and validated a machine learning model for predicting postoperative delirium. This model may facilitate prediction of postoperative delirium.

01 Aug 2024·British Journal of Pharmacology

Bardoxolone methyl prevents metabolic dysfunction‐associated steatohepatitis by inhibiting macrophage infiltration

Article

Author: Isayama, Keishiro ; Onuma, Kazuhiro ; Ogi, Sayaka ; Tokunaga, Yasunori ; Watanabe, Kenji ; Mizukami, Yoichi

AbstractBackground and PurposeBardoxolone methyl (2‐cyano‐3,12‐dioxooleana‐1,9(11)‐dien‐28‐oic acid methyl ester, CDDO‐Me) is a potent activator of nuclear factor erythroid 2‐related factor 2 (Nrf2), which induces the expression of antioxidative‐associated genes. CDDO‐Me exerts protective effects against chronic inflammatory diseases in the kidneys and lungs. However, its pharmacological effects on metabolic dysfunction‐associated steatohepatitis (MASH) caused by fat accumulation remain unknown. In this study, we examined the hepatoprotective effects of CDDO‐Me in a diet‐induced MASH mouse model and elucidated its pharmacological mechanisms using RNA‐seq analysis.Experimental ApproachCDDO‐Me was orally administered to mice fed a choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD), and histological, biochemical, and transcriptomic analyses were performed on livers of mice that developed MASH.Key resultsCDDO‐Me administration induced the expression of antioxidant genes and cholesterol transporters downstream of Nrf2 and significantly prevented the symptoms of MASH. Whole‐transcriptome analysis revealed that CDDO‐Me inhibited the inflammatory pathway that led to phagocyte recruitment, in addition to activating the Nrf2‐dependent pathway. Among inflammatory pathways, CC chemokine ligands (CCL)3 and CCL4, which are downstream of NF‐κB and are associated with the recruitment of macrophages expressing CC chemokine receptors (CCR)1 and CCR5, were released into the blood in MASH mice. However, CDDO‐Me directly inhibited the expression of CCL3‐CCR1 and CCL4‐CCR5 in macrophages.Conclusions and ImplicationsOverall, we revealed the potent hepatoprotective effect of CDDO‐Me in a MASH mouse model and demonstrated that its pharmacological effects were closely associated with a reduction of macrophage infiltration, through CCL3‐CCR1 and CCL4‐CCR5 inhibition, in addition to Nrf2‐mediated hepatoprotective effects.

01 Jul 2024·Pancreas

Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001)

Article

Author: Tokumitsu, Yukio ; Nishimura, Taku ; Hamano, Kimikazu ; Tanaka, Hidekazu ; Yahara, Noboru ; Ioka, Tatsuya ; Takami, Taro ; Nagano, Hiroaki ; Inokuchi, Toshihiro ; Matsui, Hiroto ; Harada, Eijiro ; Takahashi, Tsuyoshi ; Ito, Katsuyoshi ; Maeda, Yoshinari ; Kubo, Hidefumi ; Nakajima, Masao ; Shindo, Yoshitaro ; Kawaoka, Toru

ObjectivesThe present multicenter prospective observational study investigated the effectiveness and safety of neoadjuvant chemotherapy (NAC) for patients with borderline resectable pancreatic cancer (BRPC) and those with RPC contacting major vessels, with respect to a historical control of upfront surgery.Materials and MethodsPatients with BRPC and RPC contacting major vessels were prospectively registered and administered NAC with durations and regimens determined by the corresponding treating physician. Our primary aim was to assess the R0 resection rate, and secondary aim was to evaluate safety, resection rate, time to treatment failure, overall survival, and response rate.ResultsFifty of 52 enrolled patients were analyzed; 2 with serious comorbidities died during treatment. Thirty-one patients underwent resection, with R0 resection being achieved in 26 (52% of total and 84% of all resected cases). Univariate and multivariate analyses indicated age (≥75 years) as the only independent predictor of nonresection. Median progression-free survival and median survival time were longer in the prospective cohort than in the historical cohort.ConclusionsOverall, NAC for BRPC in real-world setting might yield R0 resection rates similar to those reported in previous clinical studies. Development of safe regimens and management strategies that can maintain treatment intensity in geriatric patients is warranted.

News (Medical) associated with UBE Corp.

18 Apr 2024

·www.prnewswire.com

Star Gala inspires $2.3 million in giving to support Children's Minnesota neuroscience program and first-of-its kind pediatric surgery suite

MINNEAPOLIS and ST. PAUL, Minn., April 18, 2024 /PRNewswire/ -- Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program. Star Gala is regarded as one of the biggest nights of the year for the Twin Cities philanthropic community. This year's event supported The Kid Experts® at Children's Minnesota who treat a wide range of nervous system illnesses and injuries such as concussions, brain tumors, epilepsy and rare disorders in kids from birth to age 21. Donations also supported The Richard M. Schulze Family Foundation iMRI Surgical Suite, a state-of-the-art surgery facility at Children's Minnesota that is the first of its kind in North America. "The Children's Minnesota neuroscience program strives to serve as both a trusted resource and a beacon of hope for patient families across our region seeking expert care for their child's brain or nervous system condition – establishing and maintaining that trust is built on providing world class care, cutting-edge technology and pioneering research," said Dr. Meysam Kebriaei, medical director of the neurosurgery program at Children's Minnesota. "Philanthropy is absolutely critical to this mission. I'm grateful to everyone who supported this year's Star Gala and to our generous community who supports our organization year-round." The 32nd annual Star Gala, hosted by KARE 11's Rena Sarigianopoulos, brought business leaders, philanthropists and community members to The Depot in Minneapolis on Saturday, April 13. Previous Star Galas supported life-saving programs at Children's Minnesota such as neonatology, cancer and blood disorders and genomic medicine. Star Gala was made possible by presenting sponsor APi Group with additional support from Best Buy, Co. Inc., Great Clips and UnitedHealth Group. B-roll of The Richard M. Schulze Family Foundation iMRI Surgical Suite is available here. About Children's Minnesota Children's Minnesota is one of the largest pediatric health systems in the United States and the only one in Minnesota devoted exclusively to children, from before birth through young adulthood. An independent and not-for-profit system for more than 100 years, Children's Minnesota offers more than 60 pediatric specialties through its two hospitals, multiple specialty centers and clinics throughout the metro area. The Kid Experts® at Children's Minnesota are chosen by more families than any other pediatric health system in the region. Find us on Facebook @childrensminnesota or on Twitter and Instagram @childrensmn. Please visit childrensMN.org. SOURCE Children's Minnesota

02 Feb 2024

·www.prnewswire.com

Mitsubishi Chemical Group Corp Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- The "Mitsubishi Chemical Group Corporation - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering. This report provides insight into Mitsubishi Chemical's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts. Mitsubishi Chemical Group Corp (MCGC), formerly Mitsubishi Chemical Holdings Corp is a diversified chemical company. Its products and services include advanced polymers, high-performance chemicals, high-performance films, advanced moldings and composites, petrochemicals, carbon, industrial gases, methyl methacrylate, and environment and living solutions. MCGC also provides ethical pharmaceuticals, diagnostic reagents and instruments, capsules and pharmaceutical equipment, active pharmaceutical ingredients and intermediates, and self-health check services. The company serves several sectors, including mobility, environment and new energy, information technology, electronics and display, medical, food and bio products, packaging, labels and films and healthcare. In June 2022, MCHG and Plug and Play Japan launched the TANAMIN Digital Health Challenge. This challenge will accept submissions from digital health startups proposing cutting-edge technology solutions to improve well-being of ALS patients and their families, digitalize Decentralized Clinical Trial, or increase preventative vaccinations in Japan. Finalists of the challenge will be offered an opportunity to pursue a paid proof of concept with MCHG, opening a potential long-term partnership with Mitsubishi Tanabe Pharma. Launched in December 2022, Growth Garage Business Incubator of Advanced Materials Division of Mitsubishi Chemical Group is inviting entrepreneurs, innovators and founders focused on lightweight parts and applications with carbon fiber-reinforced plastics (CFRP), to submit their idea to the composite Engineering Challenge. The winners of challenge will gain access to technology resources and support in material selection, tool design, scalability, and design for manufacturing. Additionally, the winners will also receive a support package of $25,000, access to industry experts, Mitsubishi's corporate venture capital arm and network to create global exposure. Scope Mitsubishi is installing and applying digital technologies to improve business efficiency and positioned digitalization as a strategic priority in its business model to enhance customer experience and enable business transformation. The company is modernizing its approaches to maximize benefits of cloud computing, mobile devices, and next-generation network technology to tap new opportunities and enhance cost efficiencies. Mitsubishi is promoting digital technologies to realize precision medicine. For instance, it is collaborating with academia and AI venture companies to develop AI technology for drug screening, which enables accelerated drug evaluation using large-scale image data. The company also aims to apply this technology to drug screening based on genetic polymorphism and drug screening using human induced pluripotent stem (IPS) cells from patients. Mitsubishi joined the IBM Quantum Network to collaborate with IBM scientists to model and analyze the deep molecular structures of potential OLED materials on IBM Quantum devices. The research teams of Mitsubishi Chemical, Keio University, and IBM Quantum are working to better understand lithium-oxygen's potential as an energy source by using new algorithms that take advantage of quantum computing to develop lithium-oxygen batteries. Reasons to Buy Gain insights into Mitsubishi's tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches, partnership, investments and acquisition strategies. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and Other Innovation Programs Technology Focus Technology Initiatives Venture Arm: Diamond Edge Ventures Investment Acquisitions Partnership, Investment & Acquisition Network Map ICT Budget and Contracts Key Executives Contact the Publisher A selection of companies mentioned in this report includes Allganize Kebotix Circularise AM Polymers Atum3D Ube Industries Dyadic International EditForce Origin Materials Solvay Dymon Celanese ENEOS Mura Technology KBR Agilyx Linde Engineering For more information about this company profile visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

19 Dec 2022

·www.prnewswire.com

Gas separation membrane market to grow by 6.07% Y-O-Y from 2022 to 2023: Rising demand for biogas will drive growth - Technavio

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Gas separation membrane market insights - Continue Reading Technavio has announced its latest market research report titled Global Gas Separation Membrane Market 2023-2027 Vendors: 15+, Including Air Liquide SA, Air Products and Chemicals Inc., Airlane Co. Ltd., Asahi Kasei Corp., DIC Corp., Evonik Industries AG, FUJIFILM Corp., GENERON, KNM Group Berhad, Membrane Technology and Research Inc., Novamem AG, Parker Hannifin Corp., PermSelect Inc., Schlumberger Ltd., SRI International, Ube Corp., Xebec Adsorption Inc., Grasys JSC, Imtex Membranes Corp., Honeywell International Inc, among others Coverage: Parent market analysis; key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors Segments: Product (polyimide and polyamide, polysulfone, cellulose acetate, and others), end-user (water and waste treatment, food and beverage, pharmaceutical, and others), and geography (North America, Europe, APAC, Middle East and Africa, and South America) To understand more about the gas separation membrane market, request a sample report The gas separation membrane market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects. Why buy? Add credibility to strategy Analyzes competitor's offerings Get a holistic view of the market Grow your profit margin with Technavio - Buy the report In 2017, the gas separation membrane market was valued at USD 1,687.95 million. From a regional perspective, North America held the largest market share, valued at USD 535.08 million. The gas separation membrane market size is estimated to grow by USD 841.31 million from 2022 to 2027 at a CAGR of 6.3%, according to Technavio. Gas separation membrane market - Customer Landscape To help companies evaluate and develop growth strategies, the report outlines – Key purchase criteria Adoption rates Adoption lifecycle Drivers of price sensitivity For highlights on customer landscape analysis, download a sample! Global gas separation membrane market - Vendor insights The growing competition in the market is compelling vendors to adopt various growth strategies such as focusing on geographical expansion through M&A or joint ventures. Technavio report analyzes the market's competitive landscape and offers information on several market vendors, including - Air Liquide SA - The company offers wind turbine components such as hollow fiber membranes. Air Products and Chemicals Inc. - The company offers gas separation membranes such as PRISM membrane separators. Asahi Kasei Corp. - The company offers gas separation membranes such as Microza UF MF. Global gas separation membrane market – Market dynamics Major drivers Rising demand for biogas Increasing need for CO2 removal Increasing use of gas separation membranes in APAC Key challenges High price of equipment Increasing production costs Shift of end-user industries from developed countries to emerging countries Drivers and challenges have an impact on market dynamics, which can impact businesses. Find some insights from a sample report! What are the key data covered in this gas separation membrane market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the gas separation membrane market between 2023 and 2027 Precise estimation of the size of the gas separation membrane market and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the gas separation membrane market across North America, Europe, APAC, Middle East and Africa, and South America A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of gas separation membrane market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports The medical gas blenders market size is expected to increase by USD 528.37 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. This report extensively covers market segmentation by product (dual flow and tube flow) and geography (North America, Europe, Asia, and Rest of World (ROW)). The POC blood gas and electrolyte market size is expected to increase by USD 443.92 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8%. The rising geriatric population is notably driving the POC blood gas and electrolyte market growth, although factors such as stringent government regulations may impede the market growth. Browse for Technavio's health care market reports Table of contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global gas separation membrane market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on Global gas separation membrane market 2017 - 2021 ($ million) 4.2 Product Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million) 4.3 End-user Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 49 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 30: Chart on Product - Market share 2022-2027 (%) Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 32: Chart on Comparison by Product Exhibit 33: Data Table on Comparison by Product 6.3 Polyimide and polyamide - Market size and forecast 2022-2027 Exhibit 34: Chart on Polyimide and polyamide - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Polyimide and polyamide - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Polyimide and polyamide - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Polyimide and polyamide - Year-over-year growth 2022-2027 (%) 6.4 Polysulfone - Market size and forecast 2022-2027 Exhibit 38: Chart on Polysulfone - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Polysulfone - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Polysulfone - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Polysulfone - Year-over-year growth 2022-2027 (%) 6.5 Cellulose acetate - Market size and forecast 2022-2027 Exhibit 42: Chart on Cellulose acetate - Market size and forecast 2022-2027 ($ million) Exhibit 43: Data Table on Cellulose acetate - Market size and forecast 2022-2027 ($ million) Exhibit 44: Chart on Cellulose acetate - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Cellulose acetate - Year-over-year growth 2022-2027 (%) 6.6 Others - Market size and forecast 2022-2027 Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%) 6.7 Market opportunity by Product Exhibit 50: Market opportunity by Product ($ million) 7 Market Segmentation by End-user 7.1 Market segments Exhibit 51: Chart on End-user - Market share 2022-2027 (%) Exhibit 52: Data Table on End-user - Market share 2022-2027 (%) 7.2 Comparison by End-user Exhibit 53: Chart on Comparison by End-user Exhibit 54: Data Table on Comparison by End-user 7.3 Water and waste treatment - Market size and forecast 2022-2027 Exhibit 55: Chart on Water and waste treatment - Market size and forecast 2022-2027 ($ million) Exhibit 56: Data Table on Water and waste treatment - Market size and forecast 2022-2027 ($ million) Exhibit 57: Chart on Water and waste treatment - Year-over-year growth 2022-2027 (%) Exhibit 58: Data Table on Water and waste treatment - Year-over-year growth 2022-2027 (%) 7.4 Food and beverage - Market size and forecast 2022-2027 Exhibit 59: Chart on Food and beverage - Market size and forecast 2022-2027 ($ million) Exhibit 60: Data Table on Food and beverage - Market size and forecast 2022-2027 ($ million) Exhibit 61: Chart on Food and beverage - Year-over-year growth 2022-2027 (%) Exhibit 62: Data Table on Food and beverage - Year-over-year growth 2022-2027 (%) 7.5 Pharmaceutical - Market size and forecast 2022-2027 Exhibit 63: Chart on Pharmaceutical - Market size and forecast 2022-2027 ($ million) Exhibit 64: Data Table on Pharmaceutical - Market size and forecast 2022-2027 ($ million) Exhibit 65: Chart on Pharmaceutical - Year-over-year growth 2022-2027 (%) Exhibit 66: Data Table on Pharmaceutical - Year-over-year growth 2022-2027 (%) 7.6 Others - Market size and forecast 2022-2027 Exhibit 67: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 68: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 69: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 70: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.7 Market opportunity by End-user Exhibit 71: Market opportunity by End-user ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 73: Chart on Market share by geography 2022-2027 (%) Exhibit 74: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 75: Chart on Geographic comparison Exhibit 76: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 APAC - Market size and forecast 2022-2027 Exhibit 85: Chart on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on APAC - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on APAC - Year-over-year growth 2022-2027 (%) 9.6 Middle East and Africa - Market size and forecast 2022-2027 Exhibit 89: Chart on Middle East and Africa - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on Middle East and Africa - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on Middle East and Africa - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on Middle East and Africa - Year-over-year growth 2022-2027 (%) 9.7 South America - Market size and forecast 2022-2027 Exhibit 93: Chart on South America - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on South America - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on South America - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on South America - Year-over-year growth 2022-2027 (%) 9.8 US - Market size and forecast 2022-2027 Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%) 9.9 Germany - Market size and forecast 2022-2027 Exhibit 101: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 102: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 103: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 104: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.10 UK - Market size and forecast 2022-2027 Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.11 China - Market size and forecast 2022-2027 Exhibit 109: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 110: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 111: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 112: Data Table on China - Year-over-year growth 2022-2027 (%) 9.12 Japan - Market size and forecast 2022-2027 Exhibit 113: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 114: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 115: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 116: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.13 Market opportunity by geography Exhibit 117: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 118: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 119: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 120: Overview on factors of disruption 11.4 Industry risks Exhibit 121: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 122: Vendors covered 12.2 Market positioning of vendors Exhibit 123: Matrix on vendor position and classification 12.3 Air Liquide SA Exhibit 124: Air Liquide SA - Overview Exhibit 125: Air Liquide SA - Business segments Exhibit 126: Air Liquide SA - Key news Exhibit 127: Air Liquide SA - Key offerings Exhibit 128: Air Liquide SA - Segment focus 12.4 Air Products and Chemicals Inc. Exhibit 129: Air Products and Chemicals Inc. - Overview Exhibit 130: Air Products and Chemicals Inc. - Business segments Exhibit 131: Air Products and Chemicals Inc. - Key news Exhibit 132: Air Products and Chemicals Inc. - Key offerings Exhibit 133: Air Products and Chemicals Inc. - Segment focus 12.5 Asahi Kasei Corp. Exhibit 134: Asahi Kasei Corp. - Overview Exhibit 135: Asahi Kasei Corp. - Business segments Exhibit 136: Asahi Kasei Corp. - Key news Exhibit 137: Asahi Kasei Corp. - Key offerings Exhibit 138: Asahi Kasei Corp. - Segment focus 12.6 DIC Corp. Exhibit 139: DIC Corp. - Overview Exhibit 140: DIC Corp. - Business segments Exhibit 141: DIC Corp. - Key news Exhibit 142: DIC Corp. - Key offerings Exhibit 143: DIC Corp. - Segment focus 12.7 Evonik Industries AG Exhibit 144: Evonik Industries AG - Overview Exhibit 145: Evonik Industries AG - Business segments Exhibit 146: Evonik Industries AG - Key news Exhibit 147: Evonik Industries AG - Key offerings Exhibit 148: Evonik Industries AG - Segment focus 12.8 FUJIFILM Corp. Exhibit 149: FUJIFILM Corp. - Overview Exhibit 150: FUJIFILM Corp. - Business segments Exhibit 151: FUJIFILM Corp. - Key news Exhibit 152: FUJIFILM Corp. - Key offerings Exhibit 153: FUJIFILM Corp. - Segment focus 12.9 GENERON Exhibit 154: GENERON - Overview Exhibit 155: GENERON - Product / Service Exhibit 156: GENERON - Key offerings 12.10 Grasys JSC Exhibit 157: Grasys JSC - Overview Exhibit 158: Grasys JSC - Product / Service Exhibit 159: Grasys JSC - Key offerings 12.11 Honeywell International Inc Exhibit 160: Honeywell International Inc - Overview Exhibit 161: Honeywell International Inc - Business segments Exhibit 162: Honeywell International Inc - Key news Exhibit 163: Honeywell International Inc - Key offerings Exhibit 164: Honeywell International Inc - Segment focus 12.12 KNM Group Berhad Exhibit 165: KNM Group Berhad - Overview Exhibit 166: KNM Group Berhad - Business segments Exhibit 167: KNM Group Berhad - Key offerings Exhibit 168: KNM Group Berhad - Segment focus 12.13 Membrane Technology and Research Inc. Exhibit 169: Membrane Technology and Research Inc. - Overview Exhibit 170: Membrane Technology and Research Inc. - Product / Service Exhibit 171: Membrane Technology and Research Inc. - Key offerings 12.14 Parker Hannifin Corp. Exhibit 172: Parker Hannifin Corp. - Overview Exhibit 173: Parker Hannifin Corp. - Business segments Exhibit 174: Parker Hannifin Corp. - Key news Exhibit 175: Parker Hannifin Corp. - Key offerings Exhibit 176: Parker Hannifin Corp. - Segment focus 12.15 PermSelect Inc. Exhibit 177: PermSelect Inc. - Overview Exhibit 178: PermSelect Inc. - Product / Service Exhibit 179: PermSelect Inc. - Key offerings 12.16 Schlumberger Ltd. Exhibit 180: Schlumberger Ltd. - Overview Exhibit 181: Schlumberger Ltd. - Business segments Exhibit 182: Schlumberger Ltd. - Key news Exhibit 183: Schlumberger Ltd. - Key offerings Exhibit 184: Schlumberger Ltd. - Segment focus 12.17 Ube Corp. Exhibit 185: Ube Corp. - Overview Exhibit 186: Ube Corp. - Business segments Exhibit 187: Ube Corp. - Key offerings Exhibit 188: Ube Corp. - Segment focus 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 189: Inclusions checklist Exhibit 190: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 191: Currency conversion rates for US$ 13.4 Research methodology Exhibit 192: Research methodology Exhibit 193: Validation techniques employed for market sizing Exhibit 194: Information sources 13.5 List of abbreviations Exhibit 195: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with UBE Corp.

100 Translational Medicine associated with UBE Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2 Clinical

Phase 3 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bepotastine salicylate ( H1 receptor )	Urticaria More	Approved
Betotastine besilate ( H1 receptor )	Urticaria More	Approved
Prasugrel Hydrochloride ( P2Y12 receptor )	Cerebrovascular Disorders More	Phase 3
SK-1405	Pruritus More	Phase 2
Y-40018 ( chymase )	-	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis